Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Christina T. Thiesler"'
Autor:
Ulf Diekmann, Malte Sgodda, Dirk Hoffmann, Axel Schambach, Nicolas M.B. Huber, Falk F. R. Buettner, Erdmann Rapp, Robert Weiβmann, Samanta Cajic, Christina T. Thiesler, Doris Steinemann, Laura van Diepen, Tobias Cantz, René Hennig, Christian Körner, Astrid Oberbeck, Christian Thiel, Andreas W. Kuss, Udo Reichl
Publikováno v:
Molecular & Cellular Proteomics : MCP
Molecular and Cellular Proteomics
Molecular and Cellular Proteomics
PMM2-CDG, formerly known as congenital disorder of glycosylation-Ia (CDG-Ia), is caused by mutations in the gene encoding phosphomannomutase 2 (PMM2). This disease is the most frequent form of inherited CDG-diseases affecting protein N-glycosylation
Autor:
Lars R. Jensen, Rita Gerardy-Schahn, Laura van Diepen, Axel Schambach, Oliver von Bohlen und Halbach, Andreas W. Kuss, Dirk Hoffmann, Doris Steinemann, Falk F. R. Buettner, Viola von Bohlen und Halbach, Christina T. Thiesler, Orly Elpeleg, Simon Edvardson
Publikováno v:
European journal of human genetics : EJHG. 26(12)
ST3GAL3 encodes the Golgi enzyme beta-galactoside-alpha-2,3-sialyltransferase-III that in humans forms, among others, the sialyl Lewis a (sLe(a)) epitope on proteins. Functionally deleterious variants in this gene were previously identified in patien
Autor:
Christina Alter, Sya N. Ukena, Anke Franzke, Sarvari Velaga, S. Kuhs, J.L. Beermann, Ulrike Dringenberg, Christina T. Thiesler
Publikováno v:
Transplant immunology. 45
Adoptively transferred regulatory T-cells represent a promising therapeutic approach for tolerance induction in autoimmunity and transplantation medicine. However, a major hurdle for clinical application is the manufacturing of sufficient Treg cell n
Autor:
Sandra Kuhs, Christina Alter, Ulrike Dringenberg, Sarvari Velaga, Sya N. Ukena, Christina T. Thiesler, Anke Franzke, Sven Olek
Publikováno v:
Experimental hematology. 45
Recent clinical trials have indicated the high potential of regulatory T cells (Tregs) in the prevention of acute and chronic graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation, but immune interventions require large numbe